Taking absorption and bioavailability to new levels that dramatically exceed industry standards and set new benchmarks for pharmacokinetic performance.
VESIsorb® is widely recognized as the leading drug delivery system for dramatically improving the bioavailability of poorly absorbed ingredients, like coenzyme Q10, omega-3 EFAs, curcumin, resveratrol, vitamin K2, vitamin D3, and many more. Throughout the past 30 years, the advancement and superiority of this colloidal droplet delivery system have consistently been demonstrated in well-designed pilot and peer-reviewed published pharmacokinetic studies as well as third-party published articles and comparative analyses. This technology platform is championed by leading medical and healthcare brands in every major continent with applications in nutraceuticals, pharmaceuticals, cosmetics, and medical devices.
VESIsorb® has made positive impacts in multiple markets, taking absorption and bioavailability to new levels that dramatically exceed industry standards. This allows for an unmatched range of product applications and novel formulations. It has successfully been applied to the most popular, science-backed ingredients like omega-3 EFAs, coenzyme Q10, QH ubiquinol, vitamin K2, curcumin, phytocannabinoids, vitamin D, pterostilbene, palm tocotrienols, diindolylmethane (DIM), gamma tocopherols, citrus polymethoxylated flavones (PMFs), resveratrol, krill oil, algal DHA, vitamin A (retinoids), phospholipids and beta-caryophyllene, among many others.
“Natural products utilizing VESIsorb® have historically set the benchmark for delivering superior absorption and blood plasma levels that allow the body to use more of the active ingredients. This provides confidence that health conscious consumers will receive the maximum benefits from the key ingredients found in our products.” - Dr. Barry Ritz, Nestlé Health Science
Industry Obstacle
It is clear in the scientific community that many natural ingredients are very poorly absorbed in the human body, often leading up to 95% of these ingredients wasted after consumption due to their lipophilicity and extensive first pass metabolism.
SourceOne Solution
To overcome these limitations, SourceOne has leveraged the VESIsorb® technology platform to mitigate the extensive first pass metabolism of poorly absorbed ingredients while setting new industry benchmarks for pharmacokinetic product performance (Cmax, AUC, Tmax).
Support Scientific Evidence
The superior pharmacokinetic (PK) performance of VESIsorb® formulated natural products is widely recognized in the global marketplace and has consistently been demonstrated in well-designed pilot and peer-reviewed published studies as well as third-party published articles and comparative analyses. Below are just a few examples to demonstrate the consistent pharmacokinetic improvements in VESIsorb® formulations.
Please submit additional questions or comments, and a member of our team will promptly respond personally to your inquiry.
SourceOne's network of research and technology partners is bolstered by our longstanding relationship with Vesifact AG (Zürich, Switzerland), recognized as a global pioneer in drug delivery system solutions. The leadership teams at SourceOne and Vesifact have been working together since 2005 and have successfully commercialized more than 50 VESIsorb® formulations in all six major continents.
Watch the following video to learn more about Vesifact.
